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Abstract In this observational cohort study, we examined
the prognostic value of growth and differentiation factor 15
(GDF15) in indicating and monitoring general mitochon-
drial disease severity and progression in adult carriers of the
m.3243A>G mutation.
Ninety-seven adult carriers of the m.3243A>G mutation
were included in this study. The Newcastle mitochondrial
disease adult scale was used for rating mitochondrial
disease severity. In parallel, blood was drawn for GDF15
analysis by ELISA. Forty-nine carriers were included in a
follow-up study. In a small subset of subjects of whom an
echocardiogram was available from general patient care,
myocardial deformation was assessed using two-dimen-
sional speckle-tracking strain analysis.
A moderate positive correlation was found between the
concentration of GDF15 and disease severity (r ¼ 0.59;
p < 0.001). The concentration of serum GDF15 was higher
in m.3243A>G carriers with diabetes mellitus, cardiomy-
opathy, and renal abnormalities. After a 2-year follow-up,
no significant correlation was found between the change in
disease severity and the change in the concentration of
GDF15 or between the GDF15 level at the first assessment
and the change in disease severity. In the subcohort of
patients of whom an echocardiogram was available, the
concentration of GDF15 correlated moderately to longitu-
dinal global strain (r ¼ 0.55; p ¼ 0.006; n ¼ 23) but not to
circumferential or radial strain.
Our results indicate that serum GDF15 is not a strong
surrogate marker for general mitochondrial disease severity.
Its value in indicating myocardial deformation should be
confirmed in a prospective longitudinal study.
Introduction
One of the key aspects of improving the quality of clinical
trials is the identification of biomarkers that are indicative
of clinically relevant outcome (Pfeffer et al. 2013). The
perfect biomarker, correlating closely to clinical disease
severity, would make the follow-up of patients easier,
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cheaper, and less invasive, both in clinical trials and in
regular patient care (Mayeux 2004). Moreover, since
functional measures are subject to bias (including patient
factors influencing performance, report bias, and inter- and
intrarater variability), measuring more objective disturban-
ces of physiology may seem more reliable. Several tests
have been used to indirectly measure the disturbed
mitochondrial energy metabolism in patients with mito-
chondrial disease, including the determination of lactic acid
concentration in the brain by magnetic resonance spectros-
copy or serum and serum fibroblast growth factor 21
(FGF21) (Suomalainen 2011). Although both lactic acid
and FGF21 seemed to correlate to disease severity, the
concentration during follow-up did not correlate to disease
progression (Koene et al. 2014; Lee et al. 2010).
A recent study reported growth and differentiation factor
15 (GDF15) as a potential new diagnostic biomarker for
mitochondrial disease (Kalko et al. 2014). GDF15 was
already known as a quite nonspecific biomarker for cancer,
as well as cardiac, pulmonary, renal, and gynecological
disease (Izumiya et al. 2014; Kempf and Wollert 2013;
Trovik et al. 2014; Yang et al. 2014; Breit et al. 2012;
Montoro-Garcia et al. 2012). However, the concentrations
reported in these disorders are within the 1.000–7.000 pg/
mL range (Dominguez-Rodriguez et al. 2014; Ho et al. 2013;
Izumiya et al. 2014; Montoro-Garcia et al. 2012; Trovik
et al. 2014), whereas concentrations as high as 85.252 pg/mL
were reported in patients with mitochondrial disease (Kalko
et al. 2014). A child with the m.3243A>G mutation, the
most commonly observed mutation leading to mitochondrial
disease, was reported to have a concentration of 6.999 pg/
mL (reference value, 380 pg/mL (95%CI, 59–701 pg/mL)).
To evaluate the value of GDF15 as a surrogate marker
for disease severity and disease progression, we examined
GDF15 in a large cohort of adult carriers of the
m.3243A>G mutation. Since GDF15 was previously
reported as a biomarker for symptoms associated with the
m.3243A>G mutation, such as cardiomyopathy (Hollings-
worth et al. 2012; Xu et al. 2011), diabetes mellitus
(Dominguez-Rodriguez et al. 2014), and renal failure
(Emma et al. 2012; Ho et al. 2013), we assessed these
symptoms and organ functions in more detail.
Methods
Patients
We determined the serum GDF15 concentration in adult
carriers of the m.3243A>G mutation included in our
“national inventory of patients with the m.3243A>G
mutation” study. In each subject, the heteroplasmy percent-
age in buccal mucosa cells, urinary epithelial cells (UEC),
and leukocytes was determined using pyrosequencing (de
Laat et al. 2012). A heteroplasmy percentage 5% can be
detected using this technique. Subjects with a detectable
heteroplasmy percentage in either buccal mucosa cells,
leukocytes, or UEC were considered to be carriers of the
mutation. In this national inventory, clinical disease severity
is monitored approximately 2-yearly in both symptomatic
and asymptomatic subjects carrying the m.3243A>G
mutation (de Laat et al. 2012). Clinical disease severity is
rated using the Newcastle mitochondrial disease adult scale
(NMDAS), a multidimensional clinical scale encompassing
current function (patient’s opinion), system-specific
involvement (assessment of multisystem disease), and
current clinical assessment (physical examination) (Schae-
fer et al. 2006). Carriers were rated as having asymptomatic
(NMDAS ¼ 0); mild (NMDAS ¼ 1–5), moderate
(NMDAS ¼ 6–20), or severe (NMDAS >20) mitochon-
drial disease (cutoff values based on expert opinion).
Seventy-six carriers were included in the follow-up study,
and serum of 50 of these carriers was available for analysis
(see Fig. 1 for a flowchart). For a more detailed description
of the methods, we refer to our previous study on fibroblast
growth factor 21 (FGF21) concentrations in this population
(Koene et al. 2014). Patients with cancer and pregnant
women were excluded since GDF15 is a known biomarker
for these conditions. Since cardiomyopathy, diabetes
mellitus, and renal failure – for which GDF15 is also a
biomarker – are highly prevalent in carriers of the
m.3243A>G mutation (de Laat et al. 2012), we also
evaluated the influence of these conditions on the GDF15
concentration. Microalbuminuria was defined as an albu-
min-to-creatinine ratio of >2.0 g/mol for men and >2.5 g/mol
for women, measured in a spot sample of urine. Decreased
creatinine clearance was defined as a glomerular filtration
rate <60 mL/min/1.73 m2. Carriers were classified as
having decreased creatinine clearance only, microalbumi-
nuria only, both, or neither. The presence and severity of
diabetes mellitus (DM) follows from the NMDAS (the
presence of DM was rated as DM requiring diet or
medication). The measurement of myocardial strain is
explained in more detail later in this section.
Thirty noncarrier family members were included as a
nuclear genetic and environmental matched reference
population. The maternal relatives who showed no signs
of diabetes mellitus, renal disease, or cardiac disease were
included in the study. In these subjects, heteroplasmy
percentages 4% (the assay’s detection limit) in UEC,
leukocytes, and/or buccal mucosa cells were established.
GDF15
All samples were measured in duplicate, following the
instructions of the manufacturer (R&D Biosystems, Minne-
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apolis, USA). The inter-assay and intra-assay variability for
high and low values was determined based on high and low
control samples, respectively. The functional sensitivity
determined at 20% covariance (CV) was 9.8 pg/mL. At a
level of 1,695 pg/mL, the within-assay CV was 3.5% and
the between-assay CV was 5.7%. At a level of 729 pg/mL,
the within-assay CV was 3.6% and the between-assay CV
was 2.2%. Samples with an initial intra-assay covariance
(CV) >15% were repeated. The two values obtained from
the duplicated measurements were averaged, and the mean
of these two measurements was used for further analysis.
Samples with a concentration higher than the highest
standard value were diluted and analysis was repeated.
According to the kit’s manufacturer, the assay has no cross-
reactivity with human GDF9 and GDF11. Age- and gender-
based reference values for serum GDF15 were adopted
from the Framingham Offspring Study (Ho et al. 2012)
(elevated GDF15 concentration is above the 97.5th percen-
tile matched for age and gender).
Medical Ethical Approval
This study (“national inventory of patients with the
m.3243A>Gmutation”) was approved by the regionalMedical
Research Ethics Committee. All procedures followed were in
accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national) and with the Helsinki Declaration of 1975, as revised
in 2013 (World Medical Association 2013). Informed consent
was obtained from all patients before being included in the
study.
Myocardial Strain Measurement
As part of general patient care, carriers of the m.3243A>G
mutation regularly undergo diagnostic echocardiography.
Myocardial deformation was only assessed only if an
echocardiogram was performed less than 1 year from an
available GDF15 sampling. The myocardial strain, a
measure for the deformation of the myocardium throughout
the cardiac cycle, was determined using two-dimensional
speckle-tracking strain analysis in accordance with a
previously published protocol (Bulten et al. 2014). Since
echocardiography was done as part of general patient care
and 2D strain measurement can only be performed when
the images are obtained following a specific protocol, only
a subset of carriers was included in this part of the study.
Strain values are dimensionless and are expressed in
percentages. Global longitudinal left ventricular myocardial
strain was calculated by averaging the six segments of the
4-chamber long-axis view. Global radial and circumferen-
tial myocardial strain was calculated by averaging the six
segments of the mid-cavity short-axis view (at the level of
the papillary muscles). If less than four out of six segments
Cohort of 118 m.3243A>G carriers
97 samples included in analysis of diseases
severity
76 carriers included in follow-up study
50 samples included in follow-up study
samples unavailable or insufficient
samples unavailable or insufficient
24 carriers underwent diagnostic
echocardiography using the 2D strain protocol
24 carriers included in 2D strain analysis
21 valid
circumferential strain 22 valid radial strain
23 valid longitudinal
strain
exclusion based on poor tracking or suboptimal image quality
49 carrier included in follow-up study
1 pregnant carrier excluded
Fig. 1 Flowchart of the study cohort
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showed valid tracking of the myocardium (e.g., because of
regional inferior image quality or poor tracking by the
software), the strain measurement was excluded from our
analyses.
Statistics
The absolute difference between two parameters was
calculated by subtracting the first measurement from the
second measurement. All parameters were assessed for
(log)normality. To prevent non-real values for zero values
of the NMDAS including its subdomains and symptom-
specific items, all values were increased by 1 prior to elog
transformation. The changes in GDF15 concentration and
NMDAS score were increased by 3,000 and 10, respec-
tively. Variables with a (log)normal distribution were
compared using parametric tests, and the mean and 95%
confidence intervals are reported. Variables that deviated
strongly from a (log)normal distribution were analyzed by
performing a nonparametric test, and the median and
interquartile ranges are reported. In case a high number of
tests were performed (5 or more), critical p-values were
adjusted using the Bonferroni method (i.e., critical p
¼ 0.05/n where n ¼ number of tests). Correlation coef-
ficients were interpreted in accordance with the guidelines
provided at the BMJ website (http://www.bmj.com/about-
bmj/resources-readers/publications/statistics-square-one/11-
correlation-and-regression; consulted 31-Jul-2014). Thus, a
correlation coefficient (r) of 0.80–1.0 is considered a very
strong relationship; r ¼ 0.60–0.79 is considered a strong
relationship; r ¼ 0.40–0.59 is considered a moderate
relationship; r ¼ 0.20–0.39 is considered a weak relation-
ship; and r ¼ 0.00–0.19 is considered a very weak or no
relationship.
Several covariates for GDF15 are known from literature
(Ho et al. 2012), including age, presence of diabetes
mellitus (DM), smoking (covariates with higher estimated
coefficient than 0.1), and renal failure. These, together with
other possible clinical covariates (gender, body mass index
(BMI), heteroplasmy percentage in urinary epithelial cells
(UEC) and leukocytes, and disease severity (NMDAS)),
were included as candidate predictors for GDF15. Gender,
age, BMI, heteroplasmy percentage in UEC and leukocytes,
and the concentration of GDF15 and FGF21 were consid-
ered candidate predictors for disease severity (NMDAS
score). The influence of nominal and ordinal candidate
predictors was determined by comparing between groups;
the influence of continuous data was evaluated in a bilinear
regression analysis. The influence of cardiomyopathy was
studied in more detail in a subgroup of carriers. For the
correlation between the concentration of GDF15 and strain
measurements, only echocardiography examinations per-
formed no more than 1 year from sampling were analyzed.
Forward and backward iterative multivariate linear regres-
sion models were used to determine the influence of
covariates and to determine the contribution of GDF15 in
predicting or monitoring the disease course. Possible
candidate predictors were only included for iterative
multivariate modeling if they correlated to the dependent
variable during univariate correlation analysis (p < 0.1).
Standardized regression coefficients (b) are presented for
each variable.
Because 38% of the variance in the concentration of
GDF15 is genetically determined (Ho et al. 2012), we
performed two additional analyses to correct for the effect
of kinship in our analyses. First, we performed a separate
analysis that included only the most severely affected
patient in each family (in case two family members had
the same NMDAS score, we included the youngest person
with that score, assuming a relatively more severe disease
in this person as age-related complaints are also included in
the NMDAS). Secondly, we used generalized estimating
equation models (working correlation structure: indepen-
dence, with robust standard error for correction) to confirm
the contribution of covariates and candidate predictors
found by linear regression models, corrected for kinship.
Because genetic factors between family members are not
likely to influence (intraindividual) changes in GDF15
levels during follow-up, we only used linear regression
models to determine the influence of covariates on the
change in disease severity and the concentration of GDF15
(longitudinal study). The (absolute) change in disease
severity (i.e., NMDAS score) was used as a possible
candidate predictor for the change in GDF15 concentration.
Both the change in the concentration of GDF15 and the
change in the concentration of FGF21 were included as
candidate predictors for the change in disease severity (i.e.,
NMDAS score).
All analyses were performed using IBM’s SPSS statis-
tics software packages, version 20.0.0.1.
Results
Patient Characteristics
We initially included 118 adult subjects in our national
inventory study. For a variety of reasons (e.g., the samples
were not available or had too small remaining volume for
measuring GDF15), we were unable to determine the
GDF15 levels in 21 of these subjects. No data were
excluded because of high intra-assay covariance of
GDF15 assessment. Thus, our final cohort included 97
adult carriers of the m.3243A>G mutation (Fig. 1). The
m.3243A>G mutation is not associated with a higher
prevalence of cancer, and none of our subjects was known
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to suffer from any form of cancer at the time of the study.
One patient did have a history of acute myeloid leukemia
(in remission for 8 years before samples were taken;
[GDF15] 731 (baseline) and 1926 (follow-up) pg/mL).
One pregnant woman was excluded ([GDF15] 43,304 pg/
mL) from the follow-up cohort (Moore et al. 2000). For
patient characteristics, we refer to Tables 1 and 2. Renal
function at the time of the sampling (spread, 6 months) was
known in 86 patients (89% of total). Seventy-one percent of
the total cohort had normal renal function, 17% had
microalbuminuria only, 2% had decreased creatinine clear-
ance only, and 9% suffered from both. Three patients had
had a renal transplant, two of which had moderate
transplant function (GFR 24 and 50 mL/min/1.73 m2) and
one had normal transplant function (GFR >75 mL/min/
1.73 m2). The m.3243A>G carriers came from 41 distinct
families (median, two subjects per family; range, 1–10
subjects per family). This cohort of adult carriers contained
two asymptomatic patients (2%), 18 patients with mild
mitochondrial disease (19%), 46 patients with moderate
mitochondrial disease (47%), and 31 patients with severe
mitochondrial disease (32%). Because sufficient material
was not always available, heteroplasmy percentage in UEC
is absent in two subjects; heteroplasmy percentage in
leukocytes is absent for another two patients. In these four
subjects, heteroplasmy levels 5% were established in the
other available tissue (buccal mucosa cells, leukocytes, or
UEC).
The Value of GDF15 as an Indicator of Clinical Disease
Severity
Fifty-one carriers (53%) had an elevated concentration of
GDF15 (i.e., higher than the 97.5th percentile of healthy
age- and sex-matched controls) compared to the age- and
gender-matched reference population from literature (Ho
et al. 2012). Carriers with an elevated concentration of
GDF15 had higher NMDAS scores compared to carriers
with normal concentrations of GDF15 (2,440 pg/ml (95%
CI, 1,097–5,431 pg/mL) versus 902 pg/mL (95%CI,
381–2,131 pg/mL); p ¼ < 0.001; independent sample t-
test). The correlation between the concentration of GDF15
and total NMDAS score in the cohort of m.3243A>G
carriers at baseline was r ¼ 0.59 (p < 0.001; n ¼ 97;
Pearson’s correlation coefficient) (see Fig. 2). This correla-
tion coefficient is not significantly higher (p ¼ 0.20; Fisher
r-to-z transformation) than the correlation between
NMDAS score and FGF21 (r ¼ 0.45; p < 0.001; n ¼ 93;
Spearman’s correlation coefficient) in this cohort); 95 out
of 99 patients (96%) of the current cohort are the same as in
the study of FGF21 (Koene et al. 2014). No significant
correlation was found between the heteroplasmy percentage
in UEC and the NMDAS score nor between the hetero-
plasmy percentage in leukocytes and the NMDAS score.
Among the 66 patients with asymptomatic, mild, or
moderate disease, the correlation coefficient between the
total NMDAS score and GDF15 was 0.54 (p < 0.001;
Spearman’s correlation coefficient); among the 31 patients
with severe disease, we found no significant correlation
between the total NMDAS score and the concentration of
GDF15 (Pearson’s correlation coefficient). The correlation
between the heteroplasmy level in UEC and GDF15 was
0.30 (p ¼ 0.003; n ¼ 95; Spearman’s rank coefficient).
The correlation between the heteroplasmy level in leuko-
cytes and GDF15 was 0.22 (p ¼ 0.031; n ¼ 95; Spear-
man’s rank coefficient).
Since the 97 adult carriers came from 41 families, we
minimized the role of kinship in these associations by
analyzing only the most severely affected patient in each of
the 41 families. The correlation coefficient between the
total NMDAS score and GDF15 concentration in this
cohort was r ¼ 0.46 (p ¼ 0.003; Pearson’s correlation
coefficient) and was similar (p ¼ 0.58; Fisher r-to-z
transformation) compared to the full cohort. During itera-
tive multivariate linear modeling, the following parameters
were found to be independent predictors for disease
severity: concentration of GDF15, age, concentration of
FGF21, and heteroplasmy percentage in UEC (b(GDF15)
¼ 0.38 (p < 0.001); b(age) ¼ 0.32 (p < 0.001); b(hetero-
plasmy UEC) ¼ 0.24 (p ¼ 0.005); b(FGF21) ¼ 0.21 (p
¼ 0.033; forward multilinear regression modeling)). When
GDF15 and FGF21 were included as the only independent
predictors for disease severity in a linear regression model,
only GDF15 was included (b(GDF15) ¼ 0.59 (p < 0.001);
forward multilinear regression modeling). We found a
moderate correlation between the concentration of GDF15
and the concentration of FGF21 (r ¼ 0.54; p > 0.001;
n ¼ 93; Spearman’s correlation coefficient).
Covariates for the Concentration of GDF15
The concentration of GDF15 was not higher in females
compared to males (p ¼ 0.38; general linear model). The
concentration of GDF15 was not higher among smokers
compared to nonsmokers (p ¼ 0.70; n ¼ 84; general linear
model). Patients without microalbuminuria or decreased
creatinine clearance had lower concentrations of GDF15
compared to patients with microalbuminuria only or both
microalbuminuria or decreased creatinine clearance (p
¼ 0.031 and 0.002, respectively; Tukey HSD), but not
compared to patients with decreased creatinine clearance
only (p ¼ 0.24; Tukey HSD). The subgroups with renal
abnormalities were comparable with respect to GDF15
concentrations (Tukey HSD). (see Fig. 3). The concentra-
tion of GDF15 was significantly higher in patients with any
kind of renal abnormalities compared to those without renal
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abnormalities (2,515 pg/mL (95%CI, 699–9,045 pg/mL)
versus 1,261 pg/mL (95%CI, 373–4,264 pg/mL; n ¼ 61);
p < 0.001; independent samples t-test). Carriers with
microalbuminuria had higher concentrations of GDF15
compared to those without microalbuminuria (2,574 pg/
mL (IQR, 1,937–4,069 pg/mL; n ¼ 25) versus 1,406 pg/
mL (IQR, 781–1,973 pg/mL); p < 0.001; Mann-Whitney
U test). Carriers with decreased creatinine clearance had
higher concentrations of GDF15 compared to carriers with
normal creatinine clearance including those with micro-
albuminuria only (3,418 pg/mL (IQR, 2,463–4,388 pg/mL;
n ¼ 12) versus 1,471 pg/mL (IQR, 867–2,105 pg/mL);
Mann-Whitney U test; p < 0.001).
Carriers with DM had higher concentrations of GDF15
compared to carriers without DM (1,958 pg/mL (95%CI,
579–6,620 pg/mL) versus 1,299 pg/mL (95%CI,
345–4,902 pg/mL); p ¼ 0.003; independent samples t-
test). (see Fig. 4). We found significantly higher serum
GDF15 concentrations in patients with cardiomyopathy
according to the NMDAS (including patients with asymp-
tomatic ECG changes; NMDAS cardiomyopathy  1)
compared to carriers without cardiomyopathy (2,574 pg/
mL (998–6,638) versus 1,371 pg/mL (381–4,937); p
< 0.001; independent samples t-test).
Univariate regression analysis showed that the total
NMDAS score was the only significant contributor to the
concentration of GDF15 (b(NMDAS) ¼ 0.59; p < 0.001).
In our cohort, we found no significant contribution of age
and BMI to the concentration of GDF15. Generalized
estimating equations confirmed the predictive value of
Fig. 2 Correlation between the concentration of GDF15 and disease severity in adult m.3243A>G carriers. The correlation between the
concentration of GDF15 and the total NMDAS score (disease severity) is r ¼ 0.59 (p < 0.001). Scales are loglinear
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Fig. 3 GDF15 concentrations in patients with and without renal abnormalities, including decreased creatinine clearance and microalbuminuria.
Significant differences between groups are flagged with an asterisk
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disease severity as a significant contributor to the concen-
tration of GDF15, after correcting for kinship clustering
(p < 0.001; generalized estimating equations).
The Value of GDF15 in Predicting Clinical Disease
Progression
Approximately 2 years after the initial assessment, the
GDF15 concentration and disease severity (NMDAS score)
were measured again in 76 carriers from the initial cohort of
97 carriers. Of these 76 carriers, 50 samples were available
(see Fig. 1). One carrier included in the follow-up group
was excluded because of pregnancy. The remaining 49
carriers in the follow-up study were similar compared to the
total cohort with respect to (distribution of) gender, age,
BMI, GDF15 concentration, presence and severity of DM,
cardiomyopathy, stroke-like episodes, myopathy and
encephalopathy, heteroplasmy percentage in UEC, hetero-
plasmy percentage in leukocytes, and NMDAS total and
subdomain scores (independent Mann-Whitney U test and
2-sided chi-square test). The characteristics of the entire
cohort of m.3243A>G carriers at baseline and the follow-
up cohort are summarized in Tables 1 and 2. In this follow-
up cohort, we found no significant correlation between the
change in the NMDAS score (i.e., the change in NMDAS
score between the first and second follow-up visit) and the
change in the concentration of GDF15 (i.e., the change in
GDF15 concentration between the first and the second
follow-up visit) (r ¼ 0.006; p ¼ 0.97; n ¼ 49; Spearman’s
correlation coefficient). Moreover, no significant correlation
was found between GDF15 concentration at the first visit
and change in the NMDAS (disease progression) during
follow-up (r ¼ 0.19; p ¼ 0.18; n ¼ 49; Spearman’s
correlation coefficient). Linear regression also revealed that
the change in total disease severity did not contribute
significantly to the change in the GDF15 concentration
(p ¼ 0.72; univariate linear regression). A linear regression
model revealed that the change in FGF21 concentration, but
not the change in GDF15 concentration contributed
significantly to the change in disease severity (i.e., NMDAS
score; b(FGF21) ¼ 0.45 (p ¼ 0.03; n ¼ 24); forward
multilinear regression modeling). There was no correlation
between the change in the concentration of GDF15 and the
change in the concentration of FGF21 (r ¼ 0.047;
p ¼ 0.85; n ¼ 18; Pearson’s correlation coefficient).
Myocardial Strain
Twenty-four subjects underwent echocardiographies as part
of clinical care within 1 year of GDF15 sampling. These
subjects were similar compared to the whole group with
respect to gender, age, BMI, and total NMDAS score and
cardiac and DM subscores (independent Mann-Whitney U
test and 2-sided chi-square test; see Tables 3 and 4).
Qualitative descriptions of gross echocardiography findings
include (not mutually exclusive): left ventricle (LV)
hypertrophy (n ¼ 8), LV systolic dysfunction (n ¼ 3), LV
diastolic dysfunction (n ¼ 8), mild aortic regurgitation
(n ¼ 2), and mild mitral regurgitation (n ¼ 1). Ten carriers
had normal gross echocardiography findings.
The correlation coefficient between the global longitudi-
nal strain and the concentration of GDF15 was 0.55
(p ¼ 0.006; n ¼ 23; Pearson’s correlation coefficient).
There was no correlation between global circumferential
or radial strain and the concentration of GDF15 (r ¼ 0.17;
p ¼ 0.47; n ¼ 21 and r ¼ 0.20; p ¼ 0.37; n ¼ 22, respec-
tively; Spearman’s correlation coefficients).
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Fig. 4 GDF15 concentrations in patients with and without diabetes mellitus. Significant differences are flagged with an asterisk
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Family-Matched Controls
The family-matched controls (n ¼ 30) were similar to their
maternal relatives carrying the m.3243A>G mutation with
respect to age (p ¼ 0.52; independent sample t-test), gender
(p ¼ 1.0), and smoking (p ¼ 0.29; Fisher’s exact test), but
not with respect to BMI (p ¼ 0.004; Mann-Whitney U test)
and the presence and severity of DM (p ¼ 0.001; Fisher’s
exact test) (see Table 1 and 2). The mean GDF15
concentration in the family-matched control group was
490 pg/mL (95%CI, 272–1,616 pg/mL; range,
236–1,687 pg/mL), which was significantly lower than
their relatives carrying the m.3243A>G mutation
(1,525 pg/mL (95%CI, 411–5,691 pg/mL); range,
333–7,421 pg/mL; p < 0.001; independent samples t-test).
Only one maternal family member had an elevated
concentration of GDF15 (1,560 pg/mL in an 18-year-old
female) compared to age- and gender-matched controls.
None of the maternal relatives was pregnant or known to
have cancer, renal dysfunction, or cardiac problems.
Discussion
This study explored the value of serum GDF15 in
indicating and monitoring mitochondrial disease severity
and disease progression in adult m.3243A>G carriers. We
found that the concentration of serum GDF15 correlates
moderately to disease severity but does not correlate to
disease progression in m.3243A>G carriers. Analysis of
Table 3 Patient characteristics of the cohort of all adult m.3243A>G carriers of which myocardial strain was reported
Cardiac 2D strain cohort (24 carriers) Difference from
all carriers
Central value Spread Range n p
Gender % female 75 24 0.80
Age (years) Mean, 95%CI 44 25–63 24–64 24 0.80
BMI (kg/m2) Median, IQR 22.3 21–26 18.3–35.8 24 0.91
Smoking (current) % yes 22 23 0.78
Diabetes mellitus (prevalence) % yes 45 24 0.48
Heteroplasmy percentage, leukocytes (%) Mean, 95%CI 18a 7–50 7–49 23 0.22
Heteroplasmy percentage, UEC (%) Mean, 95%CI 56 24–93 23–96 24 0.078
NMDAS score Mean, 95%CI 20 1–54 0–56 24 0.11
Domain 1 Mean, 95%CI 5a 0–23 0–23 24 0.11
Domain 2 Mean, 95%CI 8 0–23 0–23 24 0.015
Domain 3 Mean, 95%CI 3a 0–16 0–18 24 0.97
Myopathy score Mean, 95%CI 3 0–7 0–7 24 0.57
Encephalopathy score Median, IQR 2 1–5 0–11 24 0.25
Diabetes mellitus (severity) Mean, 95%CI 2 0–5 0–5 24 0.31
Cardiomyopathy (severity) Median, IQR 0 0–2 0–5 24 0.06
Stroke-like episodes (severity) Median, IQR 0 0–0 0–5 24 0.055
QoL mental Mean, 95%CI 44 27–61 25–61 24 0.055
QoL physical Mean, 95%CI 38 18–59 17–60 24 0.081
[GDF15] (pg/mL) Mean, 95%CI 1,687a 483–5,791 420–5,981 24 0.41
[FGF21] (pg/mL) Median, IQR 321 252–768 4–1,491 24 0.084
Patient characteristics for those adult carriers (n ¼ 24) for whom myocardial strain was measured. The difference at baseline between this cohort
and all carriers was calculated (chi-square test (2 sided); Fisher’s exact test (2 sided), Mann-Whitney U test; independent sample t-test). The
presence of diabetes mellitus was obtained from the NMDAS scale (score on diabetes mellitus item 3)
BMI body mass index, 95%CI 95% confidence interval, Domain 1 current function, Domain 2 system-specific involvement, Domain 3 current
clinical assessment, Encephalopathy score sum of the encephalopathic symptoms of the NMDAS (psychiatric symptoms, migraine, seizure,
stroke-like episodes, encephalopathy, and cognition), GDF15 growth and differentiation factor 15, IQR interquartile range, Myopathy score sum
of the myopathic symptoms of the NMDAS (exercise intolerance, respiratory muscle weakness, ptosis, external ophthalmoplegia, and
myopathy), n ¼ number of carriers of which data were available at that specific time point, NMDAS Newcastle mitochondrial disease adult
scale, UEC urinary epithelial cells
a Lognormal distribution
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data obtained in general patient care indicated that GDF15
might be a surrogate biomarker of left ventricular myocar-
dial strain.
So far, a few studies have found promising results
regarding the diagnostic properties of GDF15 in patients
with mitochondrial disease (Kalko et al. 2014; Yatsuga
2014). None of these studies focused on the value of
GDF15 as a surrogate marker for predicting or monitoring
disease progression. We found normal (age- and gender-
matched (Ho et al. 2012)) concentrations of GDF15 in 47%
of our carriers, including both symptomatic and asymptom-
atic individuals and in 97% of our family-matched controls.
The family-matched controls (bearing the same nuclear
genetic and environmental background as the carriers, but
without the m.3243A>G detectable in UEC, leukocytes, or
buccal mucosa cells) had significantly lower GDF15
concentrations compared to their maternal relatives carrying
the m.3243A>G mutation.
GDF15 has also been reported as a nonspecific bio-
marker for many diseases, including cancer, cardiac,
pulmonary, renal, and gynecological disease (Izumiya
et al. 2014; Kempf and Wollert 2013; Trovik et al. 2014;
Yang et al. 2014). Since several of these conditions are
highly prevalent in m.3243A>G carriers (de Laat et al.
2012; Hirano et al. 2002), including kidney failure (Breit
et al. 2012), diabetes mellitus (Dominguez-Rodriguez et al.
2014), and cardiomyopathy (Montoro-Garcia et al. 2012),
the contribution of these conditions to the concentration of
GDF15 was studied in more detail. We observed higher
concentrations of GDF15 in carriers with renal abnormal-
ities (mainly microalbuminuria) and diabetes mellitus. The
myocardial strain measured in echocardiograms collected as
part of general patient care with a maximum of 1 year apart
from GDF15 sampling indicates that GDF15 may be a
promising surrogate marker for myocardial deformity in
patients with the m.3243A>G mutation. The correlation
between the concentration of GDF15 and longitudinal
myocardial strain, but not between the concentration of
GDF15 and circumferential or radial strain (Lok et al. 2012;
St John Sutton et al. 2014), might be explained by the
observation that changes in longitudinal myocardial strain
precede changes in ejection fraction and global longitudinal
strain is now part of the recommendations in the assessment
of cardiac function, e.g., in monitoring chemotherapy
(Bates et al. 2013; Hollingsworth et al. 2012; Plana et al.
2014; St John Sutton et al. 2014). In summary, GDF15 is a
nonspecific marker that seems to be highly influenced by
several other symptoms frequently seen in this patient
group.
The previously proposed biomarker FGF21 had no
additional value to GDF15 in predicting and monitoring
disease severity in m. 3243A>G carriers. It seems neither
of the two parameters is useful as a surrogate marker for
disease severity and disease progression.
Strengths of our study include the high number of
carriers with different levels of the same mutation in their
mitochondrial genome, resulting in a heterogeneous multi-
system disease that we quantified systematically using a
standardized and quantitative follow-up, enabling us to
draw tentative conclusions regarding the value of GDF15 as
a prognostic biomarker for monitoring disease progression.
Several limitations to our study are worth mentioning. The
period of follow-up is relatively short for this slowly
progressive and often oscillating disease. The NMDAS
used in the follow-up of disease severity is not very
accurate and lacks sensitivity, making it unfit to establish
subtle changes, and in this aspect the study is underpow-
ered. The quality of the serum may have been influenced by
the storage and previous use (freeze thawing) of the
samples used in our study. Since the echocardiograms for
2D strain analysis were collected as part of clinical care, the
level of standardization was suboptimal and samples for
GDF15 analysis were not taken at the same moment as the
echocardiography. Therefore, the results of this pilot study,
Table 4 Echocardiographic characteristics of the cohort of all adult m.3243A>G carriers of which myocardial strain was reported
Cardiac ultrasound findings n %
Normal 10 42
Left ventricular hypertrophy without systolic dysfunction 8 33
Left ventricular systolic dysfunction only 2 8
Ejection fraction <55% 3 13
Left ventricular diastolic dysfunction 8 33
Dilated left ventricle 2 8
Aortic valve insufficiency (mild) 2 8
Mitral valve insufficiency (mild) 1 4
Dilated left atrium 2 8
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including the responsivity of GDF15 as a biomarker for
myocardial strain, need to be confirmed in a prospective
study. Finally, since only carriers of the m.3243A>G were
included in this study, one may not extrapolate these
findings to other causes of mitochondrial failure
The mitochondrial disease field is diligently looking for
easy-to-measure biomarkers, both for diagnostic and prog-
nostic purposes. In this study, we have demonstrated that
the concentration of serum GDF15 is moderately related to
disease severity, but not to disease progression. Although
the current study does not focus on the diagnostic
applicability of GDF15, the lack of correlation between
the concentration of GDF15 and disease progression in this
2-year follow-up study makes this biomarker unsuitable as
a prognostic biomarker. The moderate correlation between
myocardial strain and the concentration of GDF15 is a
promising starting point for finding a prognostic biomarker
for myocardial deformity but warrants further confirmation,
preferably in a longitudinal study including an in-depth
evaluation of renal function, glucose tolerance, and the
effects of pharmacological interventions.
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